Literature DB >> 11095167

Drug-induced bone loss.

P Tannirandorn1, S Epstein.   

Abstract

Bone loss leading to osteoporosis is common after the menopause and in the elderly but uncommon in normal young adults without predisposing factors. The risk factors usually associated with osteoporosis include a family history of osteoporosis or fractures, aging, prior diseases, sedentary lifestyle, low calcium intake, hypogonadism, vitamin D deficiency, smoking, and excessive alcohol consumption. However, the issue of drugs has to be considered in 'normal' individuals who present with osteoporosis or bone loss without predisposing genetic or other environmental factors. The list of drugs is extensive and includes, amongst others, glucocorticoids, thyroid hormone (excess), alcohol, medroxyprogesterone acetate, luteinizing hormone-releasing hormone agonists, anti-seizure medications, cyclosporine A, aluminium, lithium, and exchange resins. This paper reviews the pathophysiology and mechanisms of drug-induced bone loss, which includes osteoporosis and osteomalacia, and treatment concepts. Undoubtedly, physician awareness, appropriate investigation, careful prescribing, monitoring, and proper therapy for this eminently preventable side effect can preserve bone in the patients receiving bone-losing drugs.

Entities:  

Mesh:

Year:  2000        PMID: 11095167     DOI: 10.1007/s001980070062

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN: 0937-941X            Impact factor:   4.507


  14 in total

Review 1.  Medication-induced osteoporosis: screening and treatment strategies.

Authors:  Keshav Panday; Amitha Gona; Mary Beth Humphrey
Journal:  Ther Adv Musculoskelet Dis       Date:  2014-10       Impact factor: 5.346

2.  A method for determining the grade of osteoporosis based on risk factors in postmenopausal women.

Authors:  Demet Ofluoglu; Osman Hakan Gunduz; Nural Bekirolu; Evren Kul-Panza; Gulseren Akyuz
Journal:  Clin Rheumatol       Date:  2005-07-12       Impact factor: 2.980

3.  Laser-induced plasma spectroscopy (LIPS): use of a geological tool in assessing bone mineral content.

Authors:  László Andrássy; Izabella Gomez; Ágnes Horváth; Katalin Gulyás; Zsófia Pethö; Balázs Juhász; Harjit Pal Bhattoa; Zoltan Szekanecz
Journal:  Lasers Med Sci       Date:  2018-02-17       Impact factor: 3.161

4.  Bilateral tibial stress fracture in a young man due to hypercalciuric osteoporosis: a case report.

Authors:  Demet Ofluoglu; Onder Ofluoglu; Gulseren Akyuz
Journal:  Rheumatol Int       Date:  2005-08-12       Impact factor: 2.631

5.  Long-term fracture risk following renal transplantation: a population-based study.

Authors:  Line M Vautour; L Joseph Melton; Bart L Clarke; Sara J Achenbach; Ann L Oberg; James T McCarthy
Journal:  Osteoporos Int       Date:  2003-12-09       Impact factor: 4.507

6.  Antiepileptic drug use and rates of hip bone loss in older men: a prospective study.

Authors:  K E Ensrud; T S Walczak; T L Blackwell; E R Ensrud; E Barrett-Connor; E S Orwoll
Journal:  Neurology       Date:  2008-09-02       Impact factor: 9.910

Review 7.  Lithium: updated human knowledge using an evidence-based approach: part III: clinical safety.

Authors:  Etienne Marc Grandjean; Jean-Michel Aubry
Journal:  CNS Drugs       Date:  2009       Impact factor: 5.749

8.  Hip fracture risk in statin users--a population-based Danish case-control study.

Authors:  Lars Rejnmark; Mette Lena Olsen; Søren Paaske Johnsen; Peter Vestergaard; Henrik Toft Sørensen; Leif Mosekilde
Journal:  Osteoporos Int       Date:  2004-02-17       Impact factor: 4.507

9.  Bone mineral density in premenopausal women treated for node-positive early breast cancer with 2 years of goserelin or 6 months of cyclophosphamide, methotrexate and 5-fluorouracil (CMF).

Authors:  I Fogelman; G M Blake; R Blamey; M Palmer; W Sauerbrei; M Schumacher; D Serin; A Stewart; W Wilpshaar
Journal:  Osteoporos Int       Date:  2003-10-03       Impact factor: 4.507

Review 10.  Osteoporosis, schizophrenia and antipsychotics: the need for a comprehensive multifactorial evaluation.

Authors:  Uriel Halbreich
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.